An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD



Status:Completed
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:6/27/2018
Start Date:September 27, 2013
End Date:May 30, 2017

Use our guide to learn which trials are right for you!

An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD

The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment
regimens in participants with multiple myeloma who have received at least 3 prior lines of
therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are
double refractory to a PI and an IMiD.

This is an open-label (identity of assigned study drug will be known) study of daratumumab
for the treatment of participants with multiple myeloma who have received at least 3 prior
lines of therapy including a PI and an IMiD or whose disease is double refractory to both a
PI and an IMiD. Up to approximately 150 participants are to be enrolled. The study includes
screening, treatment, and follow-up phases. Participants will receive daratumumab by
intravenous infusion (28-day cycles) until disease progression, unacceptable toxicity, or
other protocol-defined reasons. For all study drug administrations, participants will receive
pre- and post-infusion medications for the prevention of infusion related reactions.
Follow-up will continue until death, loss to follow up, consent withdrawal for study
participation, or study end, whichever occurs first. The study will consist of 2 sequential
parts (Part 1 and Part 2). The purpose of Part 1 is to select a dose and schedule for Part 2
of the study. Assessment of tumor response and disease progression will be conducted
according to IMWG response criteria. Serial pharmacokinetic blood samples and a
pharmacogenomic blood sample will be collected. Safety will be monitored throughout the
study. At the end of the study, participants who are benefiting from treatment with
daratumumab will have the option to continue treatment.

Inclusion Criteria:

- Documented multiple myeloma according to protocol-defined criteria

- Evidence of disease progression on the most recent prior treatment regimen based on
International Myeloma Working Group criteria

- Eastern Cooperative Oncology Group performance status score of 0, 1, or 2

- Laboratory values and electrocardiogram within protocol-defined parameters at
screening

Exclusion Criteria:

- Received daratumumab or other anti-CD38 therapies previously

- Nonsecretory multiple myeloma

- Previously received an allogenic stem cell transplant or has received an autologous
stem cell transplantation within 12 weeks

- Exhibiting clinical signs of meningeal involvement of multiple myeloma

- Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma
within 5 years

- Seropositive for human immunodeficiency virus, hepatitis B or antibodies to hepatitis
B surface and core antigens, or hepatitis C

- Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes),
or amyloidosis
We found this trial at
18
sites
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Calgary,
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials